Enalapril carries opposite verdicts for pregnancy and lactation, and the NU553 Unit 8 brief shows why for one composite mother twelve days postpartum, citing milk-transfer data and a boxed warning. Searches like "nu 553 unit 8 assignment example", "nu553 unit 8 sample" and "nu553 unit 8 example" land here.
Enalapril While Breastfeeding, Twelve Days After Preeclampsia: A Pregnancy and Lactation Brief
[Student Name]
Purdue University Global
NU553: Advanced Pharmacology and Pharmacotherapeutics
Unit 8 Pregnancy and Lactation Brief
[Instructor Name]
[Date]
The patient is a composite; the starting amount is bracketed as a composite value and the brief is not dosing guidance.
1. The Clinical Question
Can enalapril replace nifedipine for Ms. [R.] while she breastfeeds a term infant? Her blood pressure remains above target on nifedipine extended release, and the throbbing headaches she attributes to it are making her reluctant to take it. Persistent postpartum hypertension after preeclampsia needs treatment, and ACOG (2020) recommends continued blood pressure monitoring and treatment in the weeks after delivery. Pregnancy and lactation are different exposures with different evidence, and a drug's answer to one says nothing about the other.
2. Why Enalapril Would Have Been Wrong a Month Ago
Evidence type: drug labeling and the pharmacology of the fetal renin-angiotensin system.
Enalapril, like all angiotensin-converting enzyme inhibitors, carries a boxed warning against use in pregnancy. The fetal kidney depends on angiotensin II to maintain glomerular filtration in the second and third trimesters. Blocking its formation reduces fetal kidney perfusion, leading to reduced fetal urine output, low amniotic fluid, fetal kidney injury, skull and limb abnormalities from compression, and neonatal kidney failure and low blood pressure. That is why nifedipine, labetalol and methyldopa, not ACE inhibitors, are the antihypertensives used during pregnancy.
Since 2015, drug labels no longer use pregnancy letter categories. The Pregnancy and Lactation Labeling Rule replaced them with narrative sections describing risk, clinical considerations and data for pregnancy, lactation and reproductive potential (Food and Drug Administration, 2014). This brief therefore quotes the label's narrative sections rather than a letter.
3. What Changes After Delivery
Evidence type: measured milk concentrations and infant outcome reports.
After delivery, the fetal kidney is no longer exposed. The question becomes how much drug reaches the infant through milk. In a small study of mothers taking enalapril, concentrations of enalapril and its active metabolite, enalaprilat, in breast milk were very low (Redman et al., 1990). LactMed, consulted on [September 29, 2026], summarizes the available data: the amount an exclusively breastfed infant would receive is a tiny fraction of the maternal dose, adverse effects in breastfed infants have not been reported, and enalapril is considered an acceptable choice during breastfeeding (Drugs and Lactation Database [LactMed], 2006-).
Uncertainty remains. The number of infants studied is small. Extra caution is advised for preterm infants and newborns in the first weeks of life, whose kidneys are immature and more sensitive to the renin-angiotensin system. Ms. [R.]'s son was born at term and is twelve days old, healthy and gaining weight.
4. The Plan
1. Stop nifedipine; start enalapril [composite starting amount] once daily.
2. Home blood pressure twice daily, with a target below [140/90] and a call if above [160/110] or with headache, visual change or right upper quadrant pain, which may signal worsening preeclampsia.
3. A clinic visit about ten days after the switch for blood pressure, serum potassium and kidney function.
4. Infant observation: feeding, wet diapers and alertness; any concern prompts a call to the pediatric clinician.
5. End condition: enalapril is reviewed at six weeks postpartum, when many women with preeclampsia no longer need treatment, and it must stop before any future pregnancy.
5. Contraception and a Future Pregnancy
Because enalapril is harmful in pregnancy, a contraception conversation is part of prescribing it. Ms. [R.] should know that if she wants another pregnancy, she needs to plan a switch to a pregnancy-compatible drug before conceiving, and that if she becomes pregnant unexpectedly, she should stop enalapril and call as soon as she knows. The pediatric clinician is copied on this brief so her son's clinician knows the drug his mother is taking.
References
American College of Obstetricians and Gynecologists. (2020). Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics & Gynecology, 135(6), e237-e260. https://doi.org/10.1097/AOG.0000000000003891
Drugs and Lactation Database (LactMed). (2006-). Enalapril. National Institute of Child Health and Human Development. https://www.ncbi.nlm.nih.gov/books/NBK501922/
Food and Drug Administration. (2014). Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling, 79 Fed. Reg. 72064 (December 4, 2014).
Redman, C. W. G., Kelly, J. G., & Cooper, W. D. (1990). The excretion of enalapril and enalaprilat in human breast milk. European Journal of Clinical Pharmacology, 38(1), 99. https://doi.org/10.1007/BF00314815
How this NU553 Unit 8 example is structured
The brief is built on a separation many papers blur: pregnancy and lactation are different exposures with different evidence, and a drug's answer to one says nothing about the other. Each part therefore names its own source type. Pregnancy risk rests on labeling and on the pharmacology of the fetal renin-angiotensin system; lactation safety rests on measured milk concentrations and infant outcome reports. The 2015 Pregnancy and Lactation Labeling Rule is cited to explain why the brief quotes narrative label sections instead of letter categories. Uncertainty is stated where it exists, including the small number of infants studied. The plan section returns to therapeutics, giving enalapril a target, a check date and an end condition, since stopping before a future conception is part of prescribing it now. The pediatric clinician is copied, and the brief says so in its final sentence.
Get an NU553 Unit 8 example written to your instructions
Name the agent, the trimester or the infant's age, and any other medicines from your NU553 Unit 8 case, then add the assignment wording and rubric. The opening brief comes free, due within 24-48h, and treats pregnancy and lactation as separate questions, dates every source, brackets every amount and closes on a plan that includes when the drug stops. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU553 Unit 8 questions, answered
Why not simply cite the drug's pregnancy category?
Because the letter categories were removed from prescription labels under the FDA's 2015 labeling rule, replaced by narrative summaries of human and animal data. Citing a letter now dates the paper. The stronger briefs quote the label's narrative section or a cited drug reference, give the year, and explain what kind of evidence stands behind the conclusion.
Where does lactation evidence come from?
Mostly from measured drug concentrations in milk and from reports of infants exposed through breastfeeding, gathered in references such as LactMed from the National Library of Medicine. Sample sizes are often small, so the stronger briefs say how many mother-infant pairs were studied and note factors like prematurity that would change the picture for a particular infant.
Does the brief need to address future pregnancies?
For a drug with a pregnancy warning, yes. Prescribing it after delivery creates a later decision: contraception, and a plan to switch before trying to conceive. Leaving that out makes the brief correct for today and unsafe for next year. A single paragraph naming the plan and who will revisit it is usually enough.